Currently, some hospitals have begun to use HE4 as another marker of ovarian cancer or have combined it with CA125 for monitoring and testing, although only as determined from the serum of ovarian cancer patients and not from ascites. The gene discussed is WFDC2; the disease is ovarian carcinoma.